Literature DB >> 10072300

Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells.

C Fabrizi1, R Businaro, G M Lauro, G Starace, L Fumagalli.   

Abstract

The presence of the alpha2macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2Mr/LRP) and its ligands alpha2macroglobulin (alpha2M), apoliprotein E, and plasminogen activators was detected in senile plaques of Alzheimer's disease (AD). To explore a possible role of alpha2M in neurodegenerative processes occurring in AD, we analyzed the effect of alpha2M on Abeta 25-35-induced neurotoxicity. Treatment of LAN5 human neuroblastoma cells with 10 microM beta-amyloid peptide fragment 25-35 (Abeta 25-35) for 72 h resulted in a 50% decrease in cell viability as determined by MTT incorporation and cell counts. The addition of alpha2M to the culture medium of these cells did not determine any effect, but when the activated form alpha2M* was used a dose-dependent decrease in cell viability was observed, the maximum effect being reached at 140 and 280 nM. Moreover, treatment of LAN5 cells with alpha2M* in combination with Abeta 25-35 increased the neurotoxicity of the amyloid peptide by 25%. This neurotoxic effect of alpha2M* seems to be related to its capability to bind and inactivate TGFbeta in the culture medium, since it was mimicked by a TGFbeta neutralizing antibody. A possible involvement of receptor-mediated endocytosis was ruled out, since alpha2M receptor is not present on LAN5, as revealed by RT-PCR and Western blotting experiments. The presence of alpha2M* in amyloid deposits of Alzheimer's disease has been recently reported and a possible impairment of LRP internalization processes has been hypothesized. Our data suggest that the local accumulation of alpha2M* in AD plaques may increase Abeta 25-35-induced neurotoxicity by neutralizing TGFbeta-mediated neuroprotective mechanisms. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072300     DOI: 10.1006/exnr.1998.6978

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  A 16-amino acid peptide from human alpha2-macroglobulin binds transforming growth factor-beta and platelet-derived growth factor-BB.

Authors:  D J Webb; D W Roadcap; A Dhakephalkar; S L Gonias
Journal:  Protein Sci       Date:  2000-10       Impact factor: 6.725

2.  Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction.

Authors:  James A Carroll; James F Striebel; Brent Race; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

3.  Interaction of alpha-2-macroglobulin and HSV-1 during infection of neuronal cells.

Authors:  M Alonso; A Dimitrijevic; M Recuero; E Serrano; F Valdivieso; J A López-Guerrero
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

4.  Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma.

Authors:  ZhiHua Shi; Marcelo Rudzinski; Karen Meerovitch; Frédéric Lebrun-Julien; Elena Birman; Adriana Di Polo; H Uri Saragovi
Journal:  J Biol Chem       Date:  2008-08-13       Impact factor: 5.157

5.  Characterization of the interaction between alpha2-macroglobulin and fibroblast growth factor-2: the role of hydrophobic interactions.

Authors:  Smitha Mathew; Sanja Arandjelovic; Wayne F Beyer; Steven L Gonias; Salvatore V Pizzo
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 6.  Neuroinflammation, Microglia, and Cell-Association during Prion Disease.

Authors:  James A Carroll; Bruce Chesebro
Journal:  Viruses       Date:  2019-01-15       Impact factor: 5.048

Review 7.  Neuropathology of Animal Prion Diseases.

Authors:  Leonor Orge; Carla Lima; Carla Machado; Paula Tavares; Paula Mendonça; Paulo Carvalho; João Silva; Maria de Lurdes Pinto; Estela Bastos; Jorge Cláudio Pereira; Nuno Gonçalves-Anjo; Adelina Gama; Alexandra Esteves; Anabela Alves; Ana Cristina Matos; Fernanda Seixas; Filipe Silva; Isabel Pires; Luis Figueira; Madalena Vieira-Pinto; Roberto Sargo; Maria Dos Anjos Pires
Journal:  Biomolecules       Date:  2021-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.